231 related articles for article (PubMed ID: 33147936)
1. Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells
Zeissig MN; Hewett DR; Panagopoulos V; Mrozik KM; To LB; Croucher PI; Zannettino ACW; Vandyke K
Haematologica; 2021 Dec; 106(12):3176-3187. PubMed ID: 33147936
[TBL] [Abstract][Full Text] [Related]
2. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
[TBL] [Abstract][Full Text] [Related]
3. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.
Zeissig MN; Hewett DR; Mrozik KM; Panagopoulos V; Wallington-Gates CT; Spencer A; Dold SM; Engelhardt M; Vandyke K; Zannettino ACW
Leuk Res; 2024 Apr; 139():107469. PubMed ID: 38479337
[TBL] [Abstract][Full Text] [Related]
4. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
[TBL] [Abstract][Full Text] [Related]
5. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.
Liu L; Yu Z; Cheng H; Mao X; Sui W; Deng S; Wei X; Lv J; Du C; Xu J; Huang W; Xia S; An G; Zhou W; Ma X; Cheng T; Qiu L; Hao M
Sci Rep; 2020 Nov; 10(1):20508. PubMed ID: 33239656
[TBL] [Abstract][Full Text] [Related]
7. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
8. Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
Gilchrist A; Gauntner TD; Fazzini A; Alley KM; Pyen DS; Ahn J; Ha SJ; Willett A; Sansom SE; Yarfi JL; Bachovchin KA; Mazzoni MR; Merritt JR
Br J Pharmacol; 2014 Nov; 171(22):5127-38. PubMed ID: 24990525
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
Mrozik KM; Cheong CM; Hewett D; Chow AW; Blaschuk OW; Zannettino AC; Vandyke K
Br J Haematol; 2015 Nov; 171(3):387-99. PubMed ID: 26194766
[TBL] [Abstract][Full Text] [Related]
10. CCR1 as a target for multiple myeloma.
Vallet S; Anderson KC
Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
[TBL] [Abstract][Full Text] [Related]
11. The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells.
Pevida M; Lastra A; Meana Á; Hidalgo A; Baamonde A; Menéndez L
Neuroscience; 2014 Feb; 259():113-25. PubMed ID: 24316469
[TBL] [Abstract][Full Text] [Related]
12. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.
Gilchrist A; Echeverria SL
Front Endocrinol (Lausanne); 2022; 13():846310. PubMed ID: 35399952
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity.
Trentin L; Miorin M; Facco M; Baesso I; Carraro S; Cabrelle A; Maschio N; Bortoli M; Binotto G; Piazza F; Adami F; Zambello R; Agostini C; Semenzato G
Br J Haematol; 2007 Sep; 138(5):594-602. PubMed ID: 17686053
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
Martin SK; Diamond P; Williams SA; To LB; Peet DJ; Fujii N; Gronthos S; Harris AL; Zannettino AC
Haematologica; 2010 May; 95(5):776-84. PubMed ID: 20015878
[TBL] [Abstract][Full Text] [Related]
15. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
[TBL] [Abstract][Full Text] [Related]
16. MIP-1alpha[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-alpha and LTB4.
Ramos CD; Canetti C; Souto JT; Silva JS; Hogaboam CM; Ferreira SH; Cunha FQ
J Leukoc Biol; 2005 Jul; 78(1):167-77. PubMed ID: 15831559
[TBL] [Abstract][Full Text] [Related]
17. Evidences of the cooperative role of the chemokines CCL3, CCL4 and CCL5 and its receptors CCR1+ and CCR5+ in RANKL+ cell migration throughout experimental periodontitis in mice.
Repeke CE; Ferreira SB; Claudino M; Silveira EM; de Assis GF; Avila-Campos MJ; Silva JS; Garlet GP
Bone; 2010 Apr; 46(4):1122-30. PubMed ID: 20053385
[TBL] [Abstract][Full Text] [Related]
18. Control of both myeloid cell infiltration and angiogenesis by CCR1 promotes liver cancer metastasis development in mice.
Rodero MP; Auvynet C; Poupel L; Combadière B; Combadière C
Neoplasia; 2013 Jun; 15(6):641-8. PubMed ID: 23730212
[TBL] [Abstract][Full Text] [Related]
19. The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.
Taddei SR; Queiroz-Junior CM; Moura AP; Andrade I; Garlet GP; Proudfoot AE; Teixeira MM; da Silva TA
Bone; 2013 Jan; 52(1):259-67. PubMed ID: 23059626
[TBL] [Abstract][Full Text] [Related]
20. CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets.
Bernardini G; Sciumè G; Bosisio D; Morrone S; Sozzani S; Santoni A
Blood; 2008 Apr; 111(7):3626-34. PubMed ID: 18227348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
